Science

The human surfaceome: AI flags potential cell surface drug targets overlooked by major databases

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 21:55:25 UTC.

Briefings

A recent study highlights a critical gap in drug discovery: over 65% of approved medicines target proteins on human cell surfaces, yet major biological databases disagree on which proteins are actually present. This discrepancy complicates the identification of new drug targets for developing treatments.

Key points

• Major biological databases disagree on which proteins are found on cell surfaces, creating a fundamental problem for new treatment development.
• More than 65% of approved medicines work by binding to proteins on the surface of human cells.

Context

This finding matters because it reveals a significant disconnect between existing drug approvals and the specific biological targets needed for new therapies, potentially slowing progress in treating diseases.

Limitations

The evidence is limited to a single study published in October 2026. The specific proteins identified as targets are not listed, and the study does not provide data on the impact of this disagreement on current drug development timelines or patient outcomes.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 23:41:46 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihaxz7h2fe5m5r7s76t7l7noijylmmxsrgnda6v7cuuh2ptigztzi